Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in eosinophilic gastritis with or without eosinophilic duodenitis
2022-500795-62-00Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of dupilumab in eosinophilic gastritis (EG) and eosinophilic duodenitis (EoD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Percent change in peak gastric tissue eosinophil count from baseline to week 24. Started Mar 2024; status: completed.
02
Drugs
03
Conditions
eosinophilic gastritis (EG)eosinophilic duodenitis (EoD)
Beyond the preview
Go deeper on 2022-500795-62-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500795-62-00.